Search by drug, manufacturer, or indication

Displaying 861 - 870 of 1165

Nitisinone (nitisinone)

Status:

Concluded with an LOI

Manufacturer:

Cycle Pharmaceuticals Ltd.

Indication:

Hereditary Tyrosinemia Type 1

Last updated November 28, 2018

MDK-Nitisinone (nitisinone)

Status:

Concluded with an LOI

Manufacturer:

MendeliKABS Inc

Indication:

Hereditary Tyrosinemia Type 1

Last updated November 28, 2018

Orfadin (nitisinone)

Status:

Concluded with an LOI

Manufacturer:

Sobi Canada Inc.

Indication:

Hereditary Tyrosinemia Type 1

Last updated November 28, 2018

Ilaris (canakinumab)

Status:

Concluded with an LOI

Manufacturer:

Novartis Pharmaceuticals Canada Inc.

Indication:

Systemic juvenile idiopathic arthritis

Last updated November 19, 2018

Cinqair (reslizumab)

Status:

Concluded without agreement

Manufacturer:

Teva Canada Ltd.

Indication:

Eosinophilic Asthma

Last updated November 15, 2018

Darzalex (Daratumumab)

Status:

Concluded with an LOI

Manufacturer:

Janssen Inc.

Indication:

Multiple Myeloma

Last updated November 14, 2018

Taltz (ixekizumab)

Status:

Concluded with an LOI

Manufacturer:

Eli Lilly Canada Inc.

Indication:

Psoriatic Arthritis

Last updated November 8, 2018

Viberzi (eluxadoline)

Status:

Negotiations were not pursued

Manufacturer:

Allergan Inc.

Indication:

Irritable Bowel Syndrome

Last updated November 7, 2018

Jevtana (cabazitaxel)

Status:

Concluded with an LOI

Manufacturer:

Sanofi-Aventis Canada Inc.

Indication:

Metastatic Castration-Resistant Prostate Cancer

Last updated November 7, 2018

Vemlidy (tenofovir alafenamide)

Status:

Concluded without agreement

Manufacturer:

Gilead Sciences Canada Inc.

Indication:

Hepatitis B

Last updated October 31, 2018